suxamethonium Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| quaternary ammonium compounds | 2489 | 306-40-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A quaternary skeletal muscle relaxant usually used in the form of its bromide, chloride, or iodide. It is a depolarizing relaxant, acting in about 30 seconds and with a duration of effect averaging three to five minutes. Succinylcholine is used in surgical, anesthetic, and other procedures in which a brief period of muscle relaxation is called for.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 0 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 20, 1952 | FDA | SANDOZ |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Anaphylactic shock | 229.72 | 115.90 | 46 | 436 | 4240 | 2353363 |
| Cardiac arrest | 201.77 | 115.90 | 52 | 430 | 14878 | 2342725 |
| Hyperthermia malignant | 198.29 | 115.90 | 26 | 456 | 144 | 2357459 |
| Exposure during pregnancy | 197.05 | 115.90 | 57 | 425 | 25162 | 2332441 |
| Hypotension | 174.42 | 115.90 | 55 | 427 | 32381 | 2325222 |
| Anaphylactic reaction | 166.45 | 115.90 | 41 | 441 | 9664 | 2347939 |
| Maternal exposure during pregnancy | 130.64 | 115.90 | 37 | 445 | 14826 | 2342777 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hyperthermia malignant | 291.85 | 153.25 | 41 | 364 | 288 | 1746088 |
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | M03AB01 | MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS Choline derivatives |
| FDA EPC | N0000175719 | Depolarizing Neuromuscular Blocker |
| FDA PE | N0000175733 | Neuromuscular Depolarizing Blockade |
| CHEBI has role | CHEBI:51371 | muscle relaxant |
| CHEBI has role | CHEBI:88188 | drug allergen |
| CHEBI has role | CHEBI:51372 | neuromuscular agent |
| MeSH PA | D009465 | Neuromuscular Agents |
| MeSH PA | D009466 | Neuromuscular Blocking Agents |
| MeSH PA | D009467 | Neuromuscular Depolarizing Agents |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
Drug Use (View source of the data)
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Muscle relaxation, function | indication | 11977004 | |
| General anesthesia | indication | 50697003 | |
| Skeletal Muscle Relaxation for Endotracheal Intubation | indication | ||
| Ocular hypertension | contraindication | 4210003 | DOID:9282 |
| Hypocalcemia | contraindication | 5291005 | |
| Poisoning by digitalis glycoside | contraindication | 12876009 | |
| Hyperkalemia | contraindication | 14140009 | |
| Glaucoma | contraindication | 23986001 | DOID:1686 |
| Infectious disease | contraindication | 40733004 | |
| Myxedema | contraindication | 43153006 | DOID:11634 |
| Hypokalemia | contraindication | 43339004 | |
| Burn injury | contraindication | 48333001 | |
| Bradycardia | contraindication | 48867003 | |
| Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
| Acute nephropathy | contraindication | 58574008 | |
| Hepatic failure | contraindication | 59927004 | |
| Muscular dystrophy | contraindication | 73297009 | DOID:9884 |
| Duchenne muscular dystrophy | contraindication | 76670001 | DOID:11723 |
| Third degree burn injury | contraindication | 80247002 | |
| Spinal cord injury | contraindication | 90584004 | |
| Myasthenia gravis | contraindication | 91637004 | DOID:437 |
| Fracture of bone | contraindication | 125605004 | |
| Disorder of muscle | contraindication | 129565002 | DOID:423 |
| Spasticity | contraindication | 221360009 | |
| Rhabdomyolysis | contraindication | 240131006 | |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Injury of eye region | contraindication | 282752000 | |
| Deficiency of cholinesterase | contraindication | 360607009 | |
| At risk for aspiration | contraindication | 371736008 | |
| Primary malignant neoplasm | contraindication | 372087000 | |
| Surgical procedure on eye proper | contraindication | 373353005 | |
| Fever | contraindication | 386661006 | |
| Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
| Malignant hyperthermia | contraindication | 405501007 | |
| Cardiac arrest | contraindication | 410429000 | DOID:0060319 |
| Traumatic injury | contraindication | 417746004 | |
| Cardiac Decompensation | contraindication |
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Muscle-type nicotinic acetylcholine receptor | Ion channel | AGONIST | CHEMBL | CHEMBL | |||||
| Acetylcholinesterase | Enzyme | Ki | 4.68 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4017730 | VUID |
| N0000178917 | NUI |
| C0012792 | UMLSCUI |
| D00766 | KEGG_DRUG |
| 3822002 | SNOMEDCT_US |
| 4019935 | VANDF |
| 372724004 | SNOMEDCT_US |
| 10154 | RXNORM |
| d00376 | MMSL |
| 005590 | NDDF |
| CHEBI:45652 | CHEBI |
| CHEMBL703 | ChEMBL_ID |
| CHEMBL983 | ChEMBL_ID |
| DB00202 | DRUGBANK_ID |
| I9L0DDD30I | UNII |
| 26 | INN_ID |
| 71-27-2 | SECONDARY_CAS_RN |
| 5314 | PUBCHEM_CID |
| D013390 | MESH_DESCRIPTOR_UI |
| 4004 | IUPHAR_LIGAND_ID |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Quelicin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-6629 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | NDA | 13 sections |
| QUELICIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-6970 | INJECTION, SOLUTION | 100 mg | INTRAMUSCULAR | NDA | 13 sections |
| Anectine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-3009 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | NDA | 13 sections |
| Anectine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-3411 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | NDA | 13 sections |
| Anectine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-9053 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | NDA | 13 sections |
| Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49396-0152 | INJECTION | 200 mg | PARENTERAL | ANDA | 2 sections |
| SUCCINYLCHOLINE CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1353 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | NDA | 13 sections |
| SUCCINYLCHOLINE CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51991-964 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | ANDA | 13 sections |
| SUCCINYLCHOLINE CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52584-097 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 12 sections |
| SUCCINYLCHOLINE CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52584-377 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 13 sections |
| Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69918-700 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 13 sections |
| Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70069-301 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 12 sections |
| SUCCINYLCHOLINE CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70121-1581 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 13 sections |
| Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70710-1377 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 13 sections |
| Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70771-1352 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 13 sections |
| Quelicin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71872-7026 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | NDA | 13 sections |
| Quelicin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71872-7146 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | NDA | 13 sections |
| SUCCINYLCHOLINE CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71872-7166 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 13 sections |
| Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71872-7167 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 13 sections |